Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, Fagius J, Fredrikson S, Landtblom AM, Malmeström C, Martin C, Piehl F, Runmarker B, Stawiarz L, Vrethem M, Nerman O, Andersen O.
Tedeholm H, et al. Among authors: piehl f.
Mult Scler. 2013 May;19(6):765-74. doi: 10.1177/1352458512463764. Epub 2012 Nov 1.
Mult Scler. 2013.
PMID: 23124789
Free PMC article.